IL203943A - A preparation containing peptide for the prevention or treatment of allergy to house dust mites - Google Patents

A preparation containing peptide for the prevention or treatment of allergy to house dust mites

Info

Publication number
IL203943A
IL203943A IL203943A IL20394310A IL203943A IL 203943 A IL203943 A IL 203943A IL 203943 A IL203943 A IL 203943A IL 20394310 A IL20394310 A IL 20394310A IL 203943 A IL203943 A IL 203943A
Authority
IL
Israel
Prior art keywords
preventing
peptide
composition
house dust
dust mite
Prior art date
Application number
IL203943A
Other languages
English (en)
Hebrew (he)
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40134075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL203943(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0715949A external-priority patent/GB0715949D0/en
Priority claimed from GB0716224A external-priority patent/GB0716224D0/en
Priority claimed from GB0723337A external-priority patent/GB0723337D0/en
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of IL203943A publication Critical patent/IL203943A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
IL203943A 2007-08-15 2010-02-14 A preparation containing peptide for the prevention or treatment of allergy to house dust mites IL203943A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0715949A GB0715949D0 (en) 2007-08-15 2007-08-15 Peptide with improved solubility
GB0716224A GB0716224D0 (en) 2007-08-20 2007-08-20 Peptides for vaccine
GB0723337A GB0723337D0 (en) 2007-11-28 2007-11-28 Peptide with reduced dimer formation
PCT/GB2008/002780 WO2009022156A2 (en) 2007-08-15 2008-08-15 Peptides for desensibilization against allergens

Publications (1)

Publication Number Publication Date
IL203943A true IL203943A (en) 2013-05-30

Family

ID=40134075

Family Applications (1)

Application Number Title Priority Date Filing Date
IL203943A IL203943A (en) 2007-08-15 2010-02-14 A preparation containing peptide for the prevention or treatment of allergy to house dust mites

Country Status (23)

Country Link
US (7) US8551493B2 (OSRAM)
EP (4) EP2083856B1 (OSRAM)
JP (3) JP5697447B2 (OSRAM)
KR (1) KR101699554B1 (OSRAM)
CN (2) CN103272227B (OSRAM)
AT (1) ATE482721T1 (OSRAM)
AU (1) AU2008288283B2 (OSRAM)
BR (1) BRPI0815395A2 (OSRAM)
CA (1) CA2696563A1 (OSRAM)
CY (2) CY1110981T1 (OSRAM)
DE (1) DE602008002810D1 (OSRAM)
DK (2) DK2190473T3 (OSRAM)
EA (2) EA018110B1 (OSRAM)
ES (1) ES2402956T3 (OSRAM)
HR (2) HRP20100662T1 (OSRAM)
IL (1) IL203943A (OSRAM)
MX (1) MX2010001779A (OSRAM)
NZ (2) NZ583361A (OSRAM)
PL (1) PL2083856T3 (OSRAM)
PT (2) PT2083856E (OSRAM)
SI (2) SI2190473T1 (OSRAM)
WO (4) WO2009022155A2 (OSRAM)
ZA (2) ZA201001056B (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
PT2083856E (pt) * 2007-08-15 2010-12-23 Circassia Ltd Péptidos para a dessensibilização contra alergénios
JP5705113B2 (ja) * 2008-08-15 2015-04-22 サーカッシア リミテッド Ｉｌ−１０産生の刺激のためのアレルゲン由来のｔ細胞抗原
ES2378870T5 (es) * 2008-08-15 2016-02-03 Circassia Limited Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
JP5746053B2 (ja) * 2009-02-05 2015-07-08 サーカッシア リミテッド ワクチン用ペプチド
US8691522B2 (en) 2009-10-08 2014-04-08 Aeon Medix Inc. Composition comprising extracellular membrane vesicles derived from indoor air, and use thereof
CN105061571A (zh) * 2010-01-14 2015-11-18 默克专利股份公司 因脯氨酸残基突变而具有降低变应原性的真禾本科第5组变应原的变体
GB201002559D0 (en) * 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
EP3266460B1 (en) * 2010-06-03 2023-06-21 ALK-Abelló A/S Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof
ES2561825T3 (es) * 2010-09-24 2016-03-01 María R. Díaz-Torres Péptidos
EP2460824A1 (en) * 2010-12-01 2012-06-06 Biomay Ag Hypoallergenic polypeptides for the treatment of house dust mite allergy
CN104623666A (zh) 2011-04-29 2015-05-20 西莱克塔生物科技公司 用于诱导调节性b细胞的致耐受性合成纳米载体
US10195276B2 (en) * 2011-06-15 2019-02-05 Biotech Tools S.A. Method for the production of hydrolyzed allergens
MX2014001142A (es) 2011-07-29 2014-02-27 Selecta Biosciences Inc Nanoportadores sinteticos que generan respuestas inmunitarias humorales y de linfocitos t citotoxicos (ctl).
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
GB201209862D0 (en) 2012-06-01 2012-07-18 Circassia Ltd Cladosporium peptides
GB201209868D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Alternaria peptides
EP3964232A1 (en) 2012-10-30 2022-03-09 Aravax Pty Ltd Novel immunotherapeutic molecules and uses thereof
MX380164B (es) 2013-05-03 2025-03-12 Selecta Biosciences Inc Uso de una macromolécula terapéutica y una composición que comprende nanoportadores sintéticos que se unen a inmunosupresores para reducir la hipersensibilidad tipo i y tipo iv en un sujeto.
EP3003365A1 (en) * 2013-06-05 2016-04-13 Maria R. Diaz-Torres T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy
CN105307679A (zh) * 2013-06-06 2016-02-03 阿尼尔吉斯股份公司 用于治疗室内尘螨过敏的连续重叠肽
EP3049098A4 (en) * 2013-09-25 2017-08-16 Aravax Pty Ltd Novel immunotherapeutic composition and uses thereof
EA201691306A1 (ru) 2013-12-23 2016-10-31 Альк-Абелло А/С Пептидные комбинации и их применение при лечении аллергии на клещей домашней пыли
CA2943690A1 (en) 2014-03-31 2015-10-08 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof
IL292574A (en) 2014-09-07 2022-06-01 Selecta Biosciences Inc Methods and compositions for attenuating anti-viral transfer vector immune responses
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
WO2016159181A1 (ja) * 2015-03-30 2016-10-06 国立大学法人大阪大学 免疫用ペプチド、免疫用ペプチドの製造方法、それを含む免疫疾患用医薬組成物、および免疫疾患の治療方法
EA201890856A1 (ru) * 2015-09-30 2018-10-31 Бёрингер Ингельхайм Ветмедика Гмбх Улучшенные транспортные молекулы модулярного антигена и их применение у животных
KR101858840B1 (ko) 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
IL272033B2 (en) 2017-07-18 2023-09-01 Before Brands Inc Methods for the preparation of mixed allergen preparations
BR112020005212A2 (pt) * 2017-09-18 2020-09-15 Sutro Biopharma, Inc. conjugado de anticorpo, kit, composição farmacêutica, e, métodos de tratamento ou prevenção e de diagnóstico de uma doença ou condição.
CN108078891B (zh) * 2017-12-28 2021-05-07 昆明赛诺制药股份有限公司 一种含美洲大蠊精提物的保湿修复洗面奶
CN107970199B (zh) * 2018-01-03 2021-05-07 昆明赛诺制药股份有限公司 一种含美洲大蠊精提物的牙膏
CN119015406A (zh) 2019-01-23 2024-11-26 雀巢产品有限公司 制备混合型过敏原组合物的方法
CN117362453B (zh) * 2023-12-08 2024-02-27 山东硕景生物科技有限公司 一种Derf1重组抗原、其制备方法及应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3174456D1 (en) 1980-07-18 1986-05-28 Du Pont Monothioglycerol as thiol-protector in lyophilized materials
US4442212A (en) * 1980-11-10 1984-04-10 E. I. Du Pont De Nemours & Company Monothioglycerol as thiol-protector in lyophilized materials
US5126399A (en) * 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
US4906564A (en) * 1987-03-13 1990-03-06 The United States Of America As Represented By The Secretary Of The Army Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens
EP0362290A4 (en) * 1987-06-17 1991-09-25 Princess Margaret Children's Medical Research Foundation (Inc.) Cloning of mite allergens
FI891226L (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
GB8812214D0 (en) * 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
ES2013359A6 (es) 1988-11-04 1990-05-01 Corporacion Biolog Farmaceutic Procedimiento para la fabricacion de alergenos inmunogenicos polimerizados.
CA1340977C (en) 1988-11-15 2000-04-25 Monty Krieger Scavenger receptor protein and antibody thereto
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5547669A (en) * 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US6019972A (en) * 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
AU650249B2 (en) 1989-11-03 1994-06-16 Immulogic Pharmaceutical Corporation A human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
WO1992004445A1 (en) * 1990-09-11 1992-03-19 The Western Australian Research Institute For Child Health Ltd. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
US5433948A (en) * 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
JP2632603B2 (ja) 1991-03-12 1997-07-23 アサヒビール株式会社 ヒト抗ＤｅｒｆＩＩＩｇＥ抗体が結合するペプチド
US6982326B1 (en) * 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6555116B1 (en) 1991-10-12 2003-04-29 Regents Of The University Of California Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin
US7288256B1 (en) * 1991-10-16 2007-10-30 Merck Patent Gmbh T cell epitopes of the major allergens from dermatophagoides (house dust mite)
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
ATE444360T1 (de) * 1991-10-16 2009-10-15 Merck Patent Gmbh T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe)
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
AU664920B2 (en) 1992-08-14 1995-12-07 Asahi Breweries, Ltd. Peptide having allergenicity
JPH08507436A (ja) * 1992-12-31 1996-08-13 イミュロジック ファーマスーティカル コーポレイション 犬の鱗屑由来のアレルゲン性蛋白質及びペプチド並びにそれらの利用
US5697103A (en) 1993-01-11 1997-12-16 Personal Expression I, Inc. Therapeutic glove
NZ263913A (en) 1993-03-12 1997-10-24 Immulogic Pharma Corp Lol pi protein allergen from ryegrass and related peptides coding sequences, vectors, protein production and use
US6849427B1 (en) * 1993-03-12 2005-02-01 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor
DE69333979T2 (de) * 1993-04-14 2006-12-21 Heska Corp.(n.d.Ges, d.Staates Delaware), Loveland T-zell epitope der hauptallergene von dermatophagoides (hausstaubmilbe)
JPH09509135A (ja) 1993-06-02 1997-09-16 ティーヴィダブリュー テレソン インスティテュート フォー チャイルド ヘルス リサーチ 免疫寛容の誘導における利用のためのクリプティックペプチド
EP0714440A1 (en) 1993-08-13 1996-06-05 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
US6180771B1 (en) * 1993-12-08 2001-01-30 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor
JPH07215996A (ja) 1994-01-31 1995-08-15 Torii Yakuhin Kk ダニアレルゲンのｂ細胞エピトープ
US5968526A (en) * 1994-04-14 1999-10-19 Immulogic Pharamaceutical Corporation T cell epitopes of the major allergens from Dermatophagoides (house dust mite)
JPH09512014A (ja) * 1994-04-14 1997-12-02 イミユロジク・フアーマシユーチカル・コーポレーシヨン ダニアレルギー治療用の医薬ペプチド組成物
US6759234B1 (en) * 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
IL115744A (en) 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
DE19508192A1 (de) * 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
DE19545662C2 (de) * 1995-12-07 1998-11-26 Mannesmann Sachs Ag Selbstpumpendes hydropneumatisches Federbein mit innerer Niveauregulierung
DE69739062D1 (de) 1996-03-21 2008-12-04 Circassia Ltd Verwendung von kryptischen Peptiden zur Induktion von immunologischer Toleranz
NZ505324A (en) 1997-12-22 2002-11-26 Human Genome Sciences Inc Liquid and lyophilised KGF-2 polypeptide formulations used to accelerate soft tissue growth or regeneration
AU2064899A (en) 1998-01-09 1999-07-26 Circassia Limited Methods and compositions for desensitisation
FR2806727A1 (fr) * 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
ES2353347T3 (es) 2000-08-21 2011-03-01 Apitope Technology (Bristol) Limited Péptido.
AU2001286996A1 (en) * 2000-08-31 2002-03-13 Chiron Corporation Stabilized fgf formulations containing reducing agents
ATE414773T1 (de) * 2000-11-16 2008-12-15 Alk Abello As Mutante allergene
US7786257B2 (en) 2000-12-18 2010-08-31 University Of Kansas Signal-1/signal-2 bifunctional peptide inhibitors
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
FR2820425B1 (fr) 2001-02-08 2004-01-02 Commissariat Energie Atomique Melange de peptides issus d'une proteine nef et leurs applications
JP4812951B2 (ja) * 2001-03-21 2011-11-09 一般財団法人化学及血清療法研究所 特異性不明のｔ細胞のクローン化法及びその認識ペプチドリガンドの同定方法
GB0108752D0 (en) * 2001-04-06 2001-05-30 Isis Innovation Peptide epitopes and uses thereof
US20040202654A1 (en) 2001-04-09 2004-10-14 Mayo Foundation For Medical Education & Research Methods and materials for cancer treatment
AUPR775401A0 (en) * 2001-09-18 2001-10-11 Monash University Novel Epitopes and Uses Thereof
WO2003042344A2 (en) 2001-11-13 2003-05-22 Genentech, Inc. Apo2 ligand/trail formulations
US20060024334A1 (en) * 2001-12-05 2006-02-02 Mark Larche Immunotherapeutic methods and systems
AUPS148202A0 (en) 2002-04-02 2002-05-09 Monash University Immunotherapeutic and immunoprophylactic reagents
FR2841906B1 (fr) 2002-07-05 2006-08-18 Stallergenes Sa Molecule d'acide nucleique codant une preproproteine d'allergene d'un acarien du genre dermatophagoides ou euroglyphus et son utilisation pour la production dudit allergene dans les plantes
EP2351770A1 (en) 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
US20040071718A1 (en) * 2002-09-18 2004-04-15 Jaw-Ji Tsai Local nasal immunotherapy for allergen-induced airway inflammation
US8198401B2 (en) 2003-03-07 2012-06-12 London Health Sciences Centre Research Inc. Peptides associated with HLA-DR MHC class II molecule and involved in rheumatoid arthritis
US7541439B2 (en) 2003-06-26 2009-06-02 Merck Patent Gmbh Thrombopoietin proteins with improved properties
GB0315754D0 (en) * 2003-07-04 2003-08-13 Univ Aberdeen Pharmaceutical compositions
US20050053615A1 (en) * 2003-07-16 2005-03-10 Best Elaine A. Variants of mite group 1 allergens for the treatment of house dust mite allergy
AU2004288854B2 (en) 2003-11-10 2009-10-01 Arriva-Pharmaceuticals, Inc. Dry recombinant human alpha 1-antitrypsin formulation
EP1756150A2 (en) 2004-04-23 2007-02-28 Novozymes A/S Group 1 mite polypeptide variants
WO2005121166A1 (en) * 2004-06-10 2005-12-22 Monash University Novel immunointeractive molecules and uses thereof
US20060029551A1 (en) 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
JP4983258B2 (ja) * 2004-09-27 2012-07-25 株式会社林原 イソサイクロマルトオリゴ糖及びイソサイクロマルトオリゴ糖生成酵素とそれらの製造方法並びに用途
EP1843779A2 (en) 2005-02-01 2007-10-17 Attenuon, LLC Compositions containing the anti-angiogenic phscn-peptide
FR2881746B1 (fr) 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
CA2621067C (en) * 2005-09-15 2014-04-29 Alk-Abello A/S A method for quantification of allergens
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
GB0609121D0 (en) 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
US9249202B2 (en) 2006-08-11 2016-02-02 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
EP1958645A1 (en) 2007-02-13 2008-08-20 Biomay AG Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
US8148105B2 (en) 2007-03-16 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Scaleable manufacturing process for cysteine endoprotease B, isoform 2
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
PT2083856E (pt) * 2007-08-15 2010-12-23 Circassia Ltd Péptidos para a dessensibilização contra alergénios
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
GB2455108A (en) 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders

Also Published As

Publication number Publication date
CY1110981T1 (el) 2015-06-11
WO2009022156A2 (en) 2009-02-19
CN101820907B (zh) 2013-05-01
US9340580B2 (en) 2016-05-17
WO2009022155A3 (en) 2009-06-04
EP2190473A2 (en) 2010-06-02
CN101820907A (zh) 2010-09-01
US20140186403A1 (en) 2014-07-03
EP2190473B1 (en) 2013-01-16
MX2010001779A (es) 2010-07-06
US8652485B2 (en) 2014-02-18
AU2008288283B2 (en) 2013-01-31
EA023303B1 (ru) 2016-05-31
WO2009022157A3 (en) 2009-06-04
CN103272227B (zh) 2014-12-10
EP2286833A3 (en) 2011-09-14
BRPI0815395A2 (pt) 2015-02-10
EP2083856B1 (en) 2010-09-29
US20110123558A1 (en) 2011-05-26
JP5697447B2 (ja) 2015-04-08
CY1116828T1 (el) 2017-03-15
HK1132194A1 (en) 2010-02-19
WO2009022154A3 (en) 2009-06-04
CN103272227A (zh) 2013-09-04
CA2696563A1 (en) 2009-02-19
EP2286833A2 (en) 2011-02-23
US20160289281A1 (en) 2016-10-06
WO2009022155A2 (en) 2009-02-19
EP2397154A3 (en) 2012-04-04
KR101699554B1 (ko) 2017-01-25
WO2009022154A2 (en) 2009-02-19
EA018110B1 (ru) 2013-05-30
HRP20130270T1 (hr) 2013-04-30
US8551493B2 (en) 2013-10-08
EP2397154A2 (en) 2011-12-21
DK2083856T3 (da) 2011-01-24
DK2190473T3 (da) 2013-03-25
HRP20100662T1 (hr) 2011-01-31
SI2083856T1 (sl) 2011-02-28
PL2083856T3 (pl) 2011-04-29
PT2397154E (pt) 2015-10-29
SI2190473T1 (sl) 2013-05-31
EP2083856A2 (en) 2009-08-05
JP2017061455A (ja) 2017-03-30
US20130336999A1 (en) 2013-12-19
HK1164700A1 (en) 2012-09-28
WO2009022156A3 (en) 2009-04-30
JP2015057393A (ja) 2015-03-26
ATE482721T1 (de) 2010-10-15
NZ583362A (en) 2012-06-29
KR20100068252A (ko) 2010-06-22
EA201070270A1 (ru) 2010-08-30
EP2397154B1 (en) 2015-07-15
US9744222B2 (en) 2017-08-29
NZ583361A (en) 2012-10-26
US20100260805A1 (en) 2010-10-14
US20170157226A1 (en) 2017-06-08
EA201070271A1 (ru) 2010-12-30
JP2010536333A (ja) 2010-12-02
WO2009022157A2 (en) 2009-02-19
DE602008002810D1 (de) 2010-11-11
AU2008288283A1 (en) 2009-02-19
ES2402956T3 (es) 2013-05-10
US20100298239A1 (en) 2010-11-25
JP6040207B2 (ja) 2016-12-07
ZA201001056B (en) 2011-04-28
PT2083856E (pt) 2010-12-23
ZA201001054B (en) 2011-04-28

Similar Documents

Publication Publication Date Title
IL203943A (en) A preparation containing peptide for the prevention or treatment of allergy to house dust mites
CY1110980T1 (el) Εμβολιο συνδυασμων πεπτιδιων εναντια στην αλλεργια απο γατες
EP2589651A3 (en) Compositions and methods comprising serine protease variants
EP2039366A4 (en) COMPOSITION CONTAINING PEPTIDE AS ACTIVE INGREDIENT
MY161534A (en) Methods of purifying polypeptides
WO2009016043A3 (en) New albumin binding compositions, methods and uses
MX2009006846A (es) Derivados de tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias.
IL210589A0 (en) The tuberculosis rv2386c protein, compositions and uses thereof
MX339060B (es) Formulaciones del factor viii.
WO2011017132A3 (en) Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2007101698A3 (en) Modified molecules which promote hematopoiesis
MX2011008179A (es) Peptidos para vacuna.
WO2008093058A3 (en) Peptides and their use
ATE514765T1 (de) Azeotropartige zusammensetzungen mit 1,1,1,2,3,3- hexafluor-3-methoxypropan und 1-brompropan
MX341064B (es) Variantes de la familia il-1.
IL213026A0 (en) TNA-a INHIBITING PEPTIDES, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF
MX2009007929A (es) Uso de un primer alergeno del grupo 2 de acaro de polvo de casa para tratar alergia a un segundo alergeno del grupo 2 de acaro de polvo de casa.
MX2007010990A (es) Agentes endoparasiticidas.
WO2009095646A3 (en) Peptides from factor viii
ZA201006443B (en) Novel immunoregularory peptides,compositions and uses thereof
GB0704352D0 (en) "Peptide, compositions and uses thereof"
AP3642A (en) Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
HK1159663A (en) Grass peptides for vaccine
IL205405A0 (en) Polypeptide compound, composition comprising the same and use thereof
AU2007903495A0 (en) Novel Peptide Compositions and Uses Thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees